Sunflower Pharmaceutical Group Co.,Ltd

XSEC:002737 Stock Report

Market Cap: CN¥12.2b

Sunflower Pharmaceutical GroupLtd Past Earnings Performance

Past criteria checks 1/6

Sunflower Pharmaceutical GroupLtd has been growing earnings at an average annual rate of 15.5%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 8.2% per year. Sunflower Pharmaceutical GroupLtd's return on equity is 18.8%, and it has net margins of 19.3%.

Key information

15.5%

Earnings growth rate

15.3%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate8.2%
Return on equity18.8%
Net Margin19.3%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Sunflower Pharmaceutical GroupLtd makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

XSEC:002737 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 244,4328551,325113
30 Jun 245,1949671,614133
31 Mar 245,4539681,834130
31 Dec 235,7001,1191,835129
30 Sep 236,1001,2091,97595
30 Jun 235,8791,1041,94895
31 Mar 235,6621,0541,863101
01 Jan 235,0958671,75295
30 Sep 224,6758131,681132
30 Jun 224,6087991,659132
31 Mar 224,4436981,696133
01 Jan 224,4617051,670132
30 Sep 214,2716681,564142
30 Jun 213,9646551,425115
31 Mar 213,7696561,270113
31 Dec 203,4625841,185114
30 Sep 203,4275091,21292
30 Jun 203,5854971,310100
31 Mar 204,0695571,502105
31 Dec 194,3715651,659118
30 Sep 194,4885911,758124
30 Jun 194,5235861,757126
31 Mar 194,5945801,813119
31 Dec 184,4725631,803121
30 Sep 184,3695241,742127
30 Jun 184,2345151,680169
31 Mar 184,1114721,683140
31 Dec 173,8554241,608110
30 Sep 173,8554261,65574
30 Jun 173,7853281,7540
31 Mar 173,4353051,5860
31 Dec 163,3643031,5390
30 Sep 163,0452301,3780
30 Jun 163,0572911,3330
31 Mar 163,0943191,3310
31 Dec 153,0353071,2980
30 Sep 152,9813071,2830
30 Jun 152,9803191,2960
31 Mar 152,8203121,2160
31 Dec 142,7193011,2120
30 Sep 142,5672681,8560
31 Dec 132,1812631,0060

Quality Earnings: 002737 has a high level of non-cash earnings.

Growing Profit Margin: 002737's current net profit margins (19.3%) are lower than last year (19.8%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 002737's earnings have grown by 15.5% per year over the past 5 years.

Accelerating Growth: 002737's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 002737 had negative earnings growth (-29.3%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-2.5%).

Return on Equity

High ROE: 002737's Return on Equity (18.8%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 13:20
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Sunflower Pharmaceutical Group Co.,Ltd is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Wen Wen ShenAvic Securities Co., Ltd
Bin WuChina Merchants Securities Co. Ltd.